

Νέα καπνικά προϊόντα

 Νομοθεσία και στάση επιστημονικής κοινότητας

Γλυνός Κωνσταντίνος

Πνευμονολόγος-Εντατικολόγος Ιατρικός Σύμβουλος **GSK**

30 Μαΐου - 2 Ιουνίου 2019 Αθήνα, *Ξενοδοχείο* Royal Olympic

Αθήνα, Ξενοδοχείο Royal Olympic

30 Maïou - 2 Iouvíou 2019



Προσωπική Δήλωση Σύγκρουσης Συμφερόντων

Εργάζομαι ως ιατρικός σύμβουλος στην εταιρεία GlaxoSmithKline

Γλυνός Κωνσταντίνος

Πνευμονολόγος-Εντατικολόγος Ιατρικός Σύμβουλος **GSK**



IS THIS THE END OF CIGARETTE SMOKING?











THE ENDS ELECTRONIC NICOTINE DELIVERY SYSTEMS



the ENDS

...and the beginners



Dautzenberg B et al. Open Journal of Respiratory Diseases 2013

USA

1.78 million students had tried ENDS by the end of 2012

United Kingdom

10% of smokers used ENDS

The number of ENDS users rose to around 1.3 million in 2013

France

For teenager's, ENDS have become not a product to aid quit tobacco but a product for experimentation and initiation of cigarette use






the ENDS & the IQOS

Type of studies	Research subject
Chemical studies	Evaluation of ENDS liquids /aerosols
Toxicological studies	Evaluation the ENDS effect on cell or animals
Clinical studies	Studies on humans

Grana R et al Circulation 2014





THE LITTLE WE KNOW ...





THE ENDS ELECTRONIC NICOTINE DELIVERY SYSTEMS

Type of studies	Research subject	The Little We Know
Chemical studies	Evaluation of ENDS liquids /aerosols	 ✓ Small amounts of heavy metals and at least 20 known carcinogens ¹ ✓ glycerol forms acrolein, which causes respiratory tract irritation ²
Toxicological studies	Evaluation the ENDS effect on cell or animals	 ✓ Cyto-toxicity in embryonic cells ^{2,} oxidative stress ^{2,3} ✓ lung tissue destruction and airway hyperreactivity in mice ✓ Memory impairment ⁷ 3
Clinical studies	Studies on humans	 ✓ cardiovascular toxicity ⁷ ✓ increased dynamic airway resistance ⁴ ✓ inhibition of pulmonary anti-viral/microbial defense mechanisms ⁵ ✓ Bronchitis, cough, and emphysema ⁷
		 ✓ COPD-emphysema pathogenesis ⁶ ✓ contact dermatitis and burns ⁷





Chemical studies

Table 1. Levels of Toxicants in E-Cigarette Aerosol Compared With Nicotine Inhaler and Cigarette Smoke

Toxicant	Range in Content in Aerosol From 12 E-Cigarette Samples per 15 Puffs*	Range in Content in Conventional Cigarette Micrograms in Mainstream Smoke From 1 Cigarette	Content in Nicotine Inhaler Mist per 15 Puffs"
Formaldehyde, µg	0.2-5.61	1.6-52	0.2
Acetaldehyde, µg	0.11-1.36	52-140	0.11
Acrolein, µg	0.07-4.19	2.4-62	ND
o-Methylbenzaldehyde, µg	0.13-0.71		0.07
Toluene, µg	ND-0.63	8.3-70	ND
p,m-xylene, µg	ND-0.2		ND
NNN, ng	ND-0.00043	0.0005-0.19	ND
NNK, ng	ND-0.00283	0.012-0.11	ND
Cadmium, ng	ND-0.022		0.003
Nickel, ng	0.011-0.029		0.019
Lead, ng	0.003-0.057		0.004

[✓] The levels of toxicants in the aerosol were lower than in cigarette smoke but higher than with a nicotine inhaler



the ENDS

Chemical studies

- \checkmark A puff of ENDS = 20% of the **nicotine** contained in a puff of a conventional cigarette.
- ✓ Propylene glycol is authorised as an additive in foods and medications

But ...

- American Chemistry Council warns against inhalation exposure to propylene glycol mists.
- ➤ When heated and vaporized:
 - X propylene glycol forms propylene oxide <u>carcinogen</u> (class 2B)
 - X glycerol forms acrolein, which causes <u>upper respiratory tract</u> irritation









Chemical studies

Secondhand Exposure- indoor Pollution

Bystanders may be exposed to nicotine and other toxins (at levels much lower than cigarettes) through passive exposure to the e-cigarette aerosol.

- ✓ **Flouris** et al : Serum cotinine in nonsmokers sitting in the chamber was similar for cigarette smoke and e-cigarette aerosol exposure
- X Schober et al: Elevated nicotine, 1,2-propanediol, glycerin, aluminum, and 7 polycyclic aromatic hydrocarbons classified as probable carcinogens







Chemical studies

Size does matter?


- X Higher e-liquid nicotine content was associated with higher particle numbers in the resulting aerosol of the ENDS¹
- X The particle size distribution and number of particles delivered by the ENDS are similar to those of conventional cigarettes ¹
- X Particle concentrations of the aerosol emitted from the electronic cigarette are 300-3000 times higher than that of the ambient air ²

Ultrafine particles












Type of studies	Research subject
Chemical studies	Evaluation of ENDS liquids /aerosols
Toxicological studies	Evaluation the ENDS effect on animals
Clinical studies	Studies on humans





the ENDS

Toxicological studies

In vitro

- ✓ ENDS vapour extracts showed significantly higher cell viability compared to CS extract.¹
- X ENDS cyto-toxicity tested in vitro with embryonic cells correlated with the flavour fluids²
- X ENDS induce DNA strand breaks and <u>cell death</u> independently of nicotine in cell lines³
- X Electronic cigarette <u>liquid increases inflammation and virus infection</u> in primary human airway epithelial cells ⁴


In vivo


- e-cigarette exposure induces **pathological responses** that result in <u>lung tissue destruction</u> and <u>airway</u> <u>hyperreactivity</u> in mice ^{3,6}
- X E-Cigarettes increases **acute lung inflammation** in exposed mice ⁵
- X electronic cigarettes and e-juices with flavorings induce <u>toxicity</u>, <u>oxidative stress</u>, and <u>inflammatory response</u> in lung epithelial cells and in mouse lung ⁷



the ENDS

Toxicological studies-In vivo








THE E-CIGARETTE MODEL

Am J Physiol Lung Cell Mol Physiol 315: L662–L672, 2018. First published August 9, 2018; doi:10.1152/ajplung.00389.2017.

RESEARCH ARTICLE | *Electronic Cigarettes: Not All Good News?*


Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice



Constantinos Glynos,¹ Sofia-Iris Bibli,²,³ Paraskevi Katsaounou,¹ Athanasia Pavlidou,¹,² Christina Magkou,⁴ Vassiliki Karavana,¹ Stavros Topouzis,⁵ Ioannis Kalomenidis,¹ Spyros Zakynthinos,¹ and ⑤ Andreas Papapetropoulos¹,²

¹George P. Livanos and Marianthi Simou Laboratories, Evangelismos Hospital, 1st Department of Pulmonary and Critical Care, National, Kapodistrian University of Athens Medical School, Greece; ²Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece; ³Institute for Vascular Signaling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; ⁴Department of Histopathology, Evangelismos Hospital, Athens, Greece; and ⁵Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece

Submitted 29 August 2017; accepted in final form 7 August 2018







RESEARCH ARTICLE | Electronic Cigarettes: Not All Good News?

Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice

Constantinos Glynos, ¹ Sofia-Iris Bibli, ^{2,3} Paraskevi Katsaounou, ¹ Athanasia Pavlidou, ^{1,2} Christina Magkou, ⁴ Vassiliki Karavana, ¹ Stavros Topouzis, ⁵ Ioannis Kalomenidis, ¹ Spyros Zakynthinos, ¹ and ³ Andreas Papapetropoulos ^{1,2}



Airway Hyperresponsiveness.





CS and PGVG-F groups exhibited a pronounced Muc-5ac production in the airways of mice and increase of the airway resistance in response to methacholine upon 3-days exposure compared to air-exposed mice



3 days or 4 weeks?

ENDs induce oxidative stress compared to air-exposed mice








3 days or 4 weeks?

ENDs induce oxidative stress compared to air-exposed mice

ENDs increases IL-1β and IL-6 compared to air-exposed mice







3 days or 4 weeks?


ENDs induce oxidative stress compared to air-exposed mice


ENDs increases IL-1β and IL-6 compared to air-exposed mice

Lung histological changes are evident after smoking but not after vaping











Type of studies	Research subject
Chemical studies	Evaluation of ENDS liquids /aerosols
Toxicological studies	Evaluation the ENDS effect on animals
Clinical studies	Studies on humans

THE ENDS ELECTRONIC NICOTINE DELIVERY SYSTEMS





The biological role of the ENDS

Clinical studies

X Vardavas 2012¹: A pilot study of healthy smokers' pulmonary function upon acute ENDS exposure -5 min:

no effect on spirometry

X increased dynamic airway resistance (18%)

X decreased FeNO (16%)

- **✓ Flouris AD 2013**²:
- ✓ Short-term effects of the ENDS on pulmonary function: no significant effect.
- ✓Only smoking induces an acute adverse effect on respiratory function
- ✓ Polosa R 2014 ³: A small retrospective study to report for the first time the effects of e-cigs in asthmatic smokers who quit or reduced their tobacco
 - √ significant improvements in spirometry data, asthma control & AHR



The biological role of the ENDS

Clinical Case Reports


Respiratory system

- ✓ Case report of electronic cigarettes possibly associated with <u>eosinophilic pneumonitis</u> in a previously healthy active-duty sailor.

 Thota D, Latham E. J Emerg Med. 2014
- ✓ A case report of subacute <u>bronchial toxicity</u> induced by an electronic cigarette.

Hureaux J. Drouet M. Urban Thorax. 2014

Cardiovascular system



Acute inhalation of vaporized nicotine increases arterial pressure in young non-smokers: a pilot study.

Cooke WH et al. Clin Auton Res. 2015



The biological role of the ENDS

Clinical Study in Greece

Acute effects of short term use of e-cigarette on airway physiology

		Nicotine=11mg				Nicotine=0mg
		COPD smokers (n=16)	Asthma smokers (n=11)	Smokers (n=28)	Non smokers (n=9)	Non smokers (n=12)
DN ₂ /L,	Pre	299±182	141±52	98±35	92±39	88±25
%pred	Post	316±185	172±65*	106±29	97±38	99±22
Raw,	Pre	0.43 ± 0.18	0.38±0.13	0.29±0.12	0.25±0.07	0.24±0.04
kPa L ⁻¹ sec ⁻¹	Post	0.47±0.17	0.40±0.11*	0.31±0.13*	0.29±0.06*	0.32±0.08**
SGaw,	Pre	0.54±0.19	0.84 ± 0.31	1.16±0.47	1.31±0.22	1.20±0.27
sec ⁻¹ kPa ⁻¹	Post	0.52±0.19	0.80 ± 0.33	1.03±0.40*	1.11±0.18*	0.95±0.18*



the ENDS Electronic Nicotine Delivery Systems

Forum of International Respiratory Societies 2014

The health risks of the ENDS, have not been adequately studied.


Because nicotine is highly addictive, affects many bodily cells and functions, and is known to have many adverse effects, it is prudent to restrict usage of he ENDS at least until their safety can be established.



Changes in smoking cessation assistance in the European Union between 2012 and 2017: pharmacotherapy versus counselling versus ecigarettes.

Use of e-cigarettes for smoking cessation assistance increased (3.7% to 9.7%)%), while use of pharmacotherapy (14.6% to 11.1%)%) and smoking cessation services (7.5% to 5.0%)%) declined

ENDS as a *smoking cessation tool?*




Source:

N=12244 adults who smoke and tried to stop or who stopped in the past year; method is coded as any (not exclusive) use



ENDS as a *smoking cessation tool?*

Research paper



ENDS as a *smoking cessation tool?*

Not statistical significance between NRTs & e-cigarette

BUT ...

- ✓ e-cigarette was compared to the less effective first line smoking cessation drug (NRTs).
- ✓ All e-cigarette had lower smoking cessation rates (4%-9%-13%) than placebo(9%-15,6%) in smoking cessation


ASCEND trial

- Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N.
- Electronic cigarettes for smoking cessation: a randomised controlled trial.
- Lancet, 2013
- O'Brien B, Knight-West O, Walker N, Parag V, Bullen C.
- E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial.
- Tob Induc Dis. 2015

ECLAT trial

- Caponnetto Pl, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R.
- EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study.
- PLoS One. 2013 Jun 24;8(6): e66317.





Odds of quitting smoking, stratified by longitudinal versus cross-sectional studies

ENDS as a *smoking cessation tool?*

E-cigarettes and smoking cessation in realworld and clinical settings: a systematic review and meta-analysis

- Odds of quitting cigarettes were 28% lower in those who used e-cigarettes compared with those who did not use e-cigarettes (odds ratio [OR] 0.72, 95% CI 0.57-0.91)
- ✓ e-cigarette use is associated with reduced smoking cessation in the real world



"While vaping may not be 100% safe, most of the chemicals causing smoking related disease are absent and the chemicals that are present pose limited danger.

Public Health England

Protecting and improving the nation's health

E-cigarettes: an evidence updateA report commissioned by Public Health England

Electronic cigarettes as a harm reduction strategy?

Who can we measure harm reduction?

- Smoking causes 2x more deaths than HIV, AIDS, alcohol abuse, motor crashes, drug use and suicide combined
- On average smokers die 10 years earlier than nonsmokers

✓ The European Commission



The use of refillable electronic e-cigarettes, and the potential exposure to e-liquids containing nicotine in high concentrations, may pose risks to public health

EUR-Lex. Report 2017



Clinical Trial

Review

Customize ...

Text availability

Abstract

Free full text

Full text

Publication dates

5 years

10 years

Custom range...

Species

Humans

Other Animals

Clear all

Show additional filters

Format: Summary - Sort by: Most Recent - Per page: 20 -

Best matches for igos:

IQOS labelling will mislead consumers.

McKelvey K et al. Tob Control. (2018)

IQOS: examination of Philip Morris International's claim of reduced exposure.

St Helen G et al. Tob Control. (2018)

Revolution or redux? Assessing IQOS through a precursor product.

Elias J et al. Tob Control. (2018)

Switch to our new best match sort order

Search results

Items: 1 to 20 of 51

<< First < Prev Page 1 of 3 Next > Last >>

Point-of-sale marketing of heated tobacco products in Israel: cause for concern.

Halpern-Felsher B.

Isr J Health Policy Res. 2019 May 27;8(1):47. doi: 10.1186/s13584-019-0316-6.

PMID: 31133053 Free Article

Similar articles

Send to ▼ Filters: Manage Filters

Sort by:

Best match

Most recent

Titles with your search terms

Tobacco-specific nitrosamines (TSNA) in heated tobacco product **IQOS**. [Tob Control. 2018]

Vascular endothelial function is impaired by aerosol from a single **IQOS** H_I [Tob Control. 2018]

Awareness, experience and prevalence of heated tobacco product, **IQO\$** [Tob Control. 2018]

See more...

▼



Database: Select

Find items





Any data for IQOS?


Type of studies	Research subject		iess than Little we Know for QOS
Chemical studies	Evaluation of IQOS aerosols	√ iÇ	OOS: evidence of pyrolysis and release of a toxicant from plastic ¹
Toxicological studies	Evaluation the IQOS effect on cell or animals	✓ co	aduces cellular toxicity with increasing concentration ² , ontributes to altered mitochondrial function ² ascular endothelial function is impaired ³ assive exposure to pollutants from CS and ENDS, IQOS in passenger cars ⁴
Clinical studies	Studies on humans	cra	ort-term use has a minimal impact on eCO, is equally effective in reducing cigarette aving and withdrawal symptoms as an e-cigarette, and is slightly preferred ⁵ 5-year single-center cohort observational study to assess differences in lung function tween users of the iQOS and CS ⁶


Torre Abore T 24410 TITO TZ-sour



Toxicological studies

IQOS: Induces cellular toxicity with increasing concentration





Sohal SS et al ERJ open 2019 Leigh NJ et al Tob Control 2018;





Any data for IQOS?

Are HTPs safer than conventional tobacco?

- ✓ Currently, there is no evidence to demonstrate that HTPs are less harmful than conventional tobacco products.
- ✓ Some tobacco industry-funded studies have claimed that there are significant reductions in the formation of and exposure to harmful and potentially harmful constituents relative to standard cigarettes.
- ✓ However, there is currently no evidence to suggest that reduced exposure to these chemicals translates to reduced risk in humans.
- ✓ Therefore, additional independent studies will be required to substantiate claims of reduced risk/harm.







European Respiratory Society

Q

HE SOCIETY ▼ CONGRESS AND EVENTS ▼ PUBLICATIONS ▼ PROFESSIONAL DEVELOPMENT ▼ RESEARCH ▼ ADVOCACY AND PATIENT RESOURCES ▼



MyERS



Membership



Publications



e-learning



ERS Vision



Healthy Lungs For Life

A. 20

ERS Position Paper on Tobacco Harm Reduction

A statement by the ERS Tobacco Control Committee

The ERS Tobacco Control Committee (TCC) published the position paper on tobacco harm reduction in May 2019.

The ERS TCC believe that current strategies which support the use of alternative nicotine delivery products for smoking cessation are not effective as they are based upon incorrect assumptions and undocumented claims about the safety and effectiveness of alternative nicotine delivery products for smoking cessation.

Therefore, the statement brings together scientifically-backed arguments for why a tobacco harm reduction strategy should not be used as a population-based strategy in tobacco control, including that harm reduction arguments are:

- Based on incorrect claims that smokers cannot or will not quit smoking
- · Reliant upon undocumented assumptions that alternative nicotine delivery products are highly effective as a smoking cessation aid
- Built on incorrect assumptions that smokers will replace conventional cigarettes with alternative nicotine delivery products
- Ignorant to the lack of evidence to show that alternative nicotine delivery products are safe for human health






ERS Position
Paper on Heated
Tobacco Products



The ERS Tobacco Control Committee (TCC) published the position paper on tobacco harm reduction in May 2019.







Human lungs are made to breath clean air

Ευχαριστώ

